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Abstract: Antibiofilm properties and the phenolic composition f propolis, collected from Bartın province of 
Turkey in the years of 2013 and 2012, were determined. Hexane, ethyl acetate and ethanol extracts of propolis 
were prepared and assessed for their antibiofilm activity (inhibition of biofilm formation and reduction of 
established biofilm) against the clinical methicilln sensitive Staphylococcus aureus (MSSA) strains and 
Staphylococcus aureus ATCC 33862.  Ethyl acetate and ethanol extracts of pr polis presented a greater 
effectiveness on biofilm inhibition of the tested bacteria compared to hexane extracts. The activity patterns 
showed slight variations in the two years.  While 0.5 mg/mL ethyl acetate, ethanol and hexane extract solutions 
of the product in 2013 inhibited 92.89, 82.98 and 47.42% of biofilm formation of MSSA M20 strain, the 
inhibition percentage of the products of 2012 were determined to be 87.14%, 75.94% and 44.89% against the 
same bacterium (MSSA M20), respectively. The results of the validated liquid chromatography-electrospray 
tandem mass spectrometry (UPLC-ESI-MS/MS) analyses showed a strong relation between the activity and the 
phenolic composition of the extracts. Phenolic contents of the ethyl acetate and ethanol extracts wererelatively 
higher than hexane extracts. Caffeic acid composition of ethyl acetate, ethanol and hexane extracts of the product 
in 2013 was detected as 23521.0, 16881.0 and 3522.8 µg/g, respectively. On the other hand, the caffeic acid 
contents of the product of 2012 was found to be lower than those of 2013 (19100.0, 10416.0 and 2322.5 µg/g for 
ethyl acetate, ethanol and hexane extracts, respectively). Consequently, the findings have shown that propolis 
extracts possessed good antibiofilm activity against clinical staphylococci, and its phenolic compositi n has been 
affected by the year of collection.   
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1. Introduction 
Formation of bacterial biofilms on biomaterials or host tissues leads to the development of 
chronic infections, as biofilms are exceptionally resistant to host immune response and 
chemotherapies [1]. Staphylococci are common cause of hospital-acquired infections, and biofilm 
formation is one of the important microbial virulence factors found in staphylococci [2-4]. As it is well 
known, multilayered cell clusters, embedded in a matrix of extracellular polysaccharide, which 
facilitates the adherence of microorganisms, creates th  biofilm. Exopolysaccharide matrix limits 
antibiotic penetration through the biofilm and acts like a diffusion barrier [5]. The biofilm matrix 
consists of various chemical compositions such as proteins, extracellular DNA (eDNA), 
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exopolysaccharides, teichoic acids and uronic acids, depending on bacterial species, strain type and 
environmental conditions [6]. 
In a biofilm matrix, bacteria are protected from both host immune system and large doses of 
traditional antimicrobial agents. Thus, biofilm related infections are difficult to eradicate [7]. 
Furthermore, the increase in the microbial resistance to antibiotics and the decrease in the number of 
newly developed antimicrobials threaten public health nd cause significant problems in treatment of 
biofilm microorganisms. This indicates the need for n vel antibacterial drugs against both planktonic 
bacteria and drug resistant biofilms.  
Searching for alternative therapies has now become a n cessity. Natural plant/animal products 
and/or their combinations with antibiotics or synthetic counterparts seem to be among the promising 
solutions [8]. Within this context, propolis has found frequent use in treatment or prevention of many 
infectious diseases. 
Propolis from different parts of the world has different chemical compositions due to the 
varying conditions of the geographical regions visited by bees [9]. The primary biologically active 
constituents of propolis are flavonoids, (hydroxyl) cinnamic acid derivatives, alcohols, aldehydes, 
phenolic acids, amino acids, lignans, triterpenes, steroids and sugars. However, phenolic compounds 
are the most abundant ones [10]. These compounds, especially the flavonoids and phenols, render 
propolis biologically valuable [11-13].  
In the last decades, several biological and pharmacological activities of propolis, such as 
antitumor, antioxidant, anti-inflammatory, antiviral, anti-parasite, antifungal, antibacterial and 
immunomodulatory effects, have been investigated [14]. However, there is insufficient information in 
the literature regarding the antibiofilm performance against Staphylococcal biofilms as well as 
chemical composition of the propolis obtained from North Anatolia. In the present article, inhibition 
effect of propolis extracts against biofilm formation and reduction of established biofilm of three 
different methicillin sensitive Staphylococcus aureus (MSSA M10, MSSA M18 and MSSA M20) and 
S. aureus ATCC 33862 have been investigated. The phenol contents of the propolis extracts were 
analyzed by using UPLC-ESI-MS/MS and principal compnent analyses. Thus, this study provides 
valuable and detailed information on antibiofilm activity of propolis against clinical S. aureus strains. 
 
2. Materials and Methods 
 
2.1. Microorganisms and Medium  
 
Three clinical isolates and a reference culture of Staphylococcus aureus ATCC 33862 were used 
as test microorganisms. The clinical isolates were identified as Methicillin Sensitive Stahpylococcus 
aureus (MSSA M10, MSSA M18 and MSSA M20), using a specific biochemical test kit (Slidex 
MRSA Detection). M10 and M20 were isolated from a blood and M18 from a urine samples. 
The bacterial strains were obtained from Bacteriology Laboratory of Pamukkale University, Biology 
Department. Bacterial cultures were inoculated in agrowth media of Tryptic Soy Broth (TSB), which 
consisted of peptone from casein (17.0 g/L), peptone from soymeal (3.0 g/L), glucose (2.5 g/L), NaCl 
(5.0 g/L) and dipotassium hydrogen phosphate (2.5 g/L). The culture was aerobically incubated and 
the growth was monitored by measuring the optical density (OD) at 600 nm. The culture suspension 
was prepared and adjusted by comparing with the use of 0.5 McFarland turbidity standard tubes 
(1.5x108 cfu/mL) for all the tests.  
 
2.2. Extraction Method 
 
 Crude samples of Apis mellifera propolis were collected from Bartın Province, which s located 
in Northern Turkey, in 2013 (BP-1) and 2012 (BP-2). After propolis samples were cooled (20 °C), 
they were separately extracted with 96% ethanol (Merck), ethyl acetate (Merck) and hexane solutions 
(Merck) (1:10 w/v) at 37 °C for 5 days in a dark environment, and then filtered with a Whatman No. 1 
filter paper. The final filtrates were evaporated to dryness on a rotary evaporator (IKA RV 10D, 
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Germany) under reduced pressure, and the samples were kept at -20 °C for antibiofilm activity 
experiments and analysis. The yields of ethanol, ethyl acetate and hexane extracts were found to be 
48.62%, 38.49% and 5.87% for BP-1 sample, and 44.69%, 41.93% and 11.29% for BP-2 sample, 
respectively.  
 
2.3. Biofilm Inhibition 
 
The antibiofilm effect of the propolis extracts against biofilm forming bacteria was tested on 96-
well polystyrene plates using crystal violet assay [15]. The bacterial cultures were grown in 5 mL TSB 
at 37 °C under aerobic conditions for 24 h.  
 In order to determine the inhibition effectiveness against biofilm formation, a bacterial 
suspension at 0.5 McFarland turbidity standard was dispensed into 96-well plates in the presence of 
TSB, supplemented with 5% glucose (w/v), containing the propolis extracts, which were dissolved in 
DMSO at concentrations of 0.1-0.5 mg/mL. The plates w re then incubated for 48 h at 37 °C, which 
was followed by washing the plates with distilled water to remove loosely attached cells. The plates 
were air-dried and then the wells were stained with 0.1% (w/v) crystal violet and incubated at room 
temperature for 15 min. Then, the plates were washed with sterile distilled water to remove any 
unabsorbed stain. To destain the wells, glacial acetic acid (33%) was added into each well and the 
absorbance at 540 nm was read on a microplate reader (Optic ivymen system 2100-C). Each 
experiment was performed in duplicate, and the percentage of biofilm inhibition was calculated using 
the following formula: 
 
[(OD growth control - OD sample) / OD growth control] x100   (1), 
 
Where OD stands for optical density. 
 
2.4. Biofilm Reduction 
 
The biofilms were allowed to form in 48 h prior to the addition of the propolis extracts at a final 
concentration of 0.5-20 mg/mL per well. Briefly, an overnight culture (0.5 McFarland turbidity), 
grown in TSB at 37 °C, was diluted at 1:100 rate in TSB, supplemented with 5% glucose (w/v), and 
200 µl of this was transferred to 96 well plates [16]. The plates were incubated at 37 °C for 48 h to 
allow cell attachment. Following the 48 h incubation period, the propolis extracts in DMSO were 
added to 96-well plates at concentrations of 0.5-20 mg/mL. The plates were further incubated for 24 h 
before the crystal violet assay was performed. 
 
2.5. Identification and Quantification of Phenolic Compounds  
 
The crude propolis samples were extracted using a similar methodology mentioned above. The 
residue was re-dissolved in methanol, filtered from Macherey-Nagel Chromafil Xtra PTFE 20/25 0.20 
µm, and 2 µL of the solutions were injected to UPLC-ESI-MS/MS. 
Analyses of the propolis samples were performed using UPLC-ESI-MS/MS, a Waters Acquity 
UPLC analyzer (Waters Corporation, Milford, MA USA), equipped with a Waters (Milford, MA 
USA) BEH C18 column (100 mm x 2.1 mm, 1.7 µm particle size) and coupled to a Waters Xevo TQ-S 
Triple Quadrupole tandem mass spectrometry, having electrospray ionization (Waters Corporation, 
Milford, MA USA). The column was eluted using a linear gradient of two mobile phases, i.e. solvent 
A (water:acetic acid; 99.95:0.05, v/v) and solvent B (acetonitrile:acetic acid; 99.95:0.05, v/v), which 
was conducted starting with 99% solvent A and subsequently decreasing it to 70% in 10 min, 5% in 2 
min, increasing to 99% in 2 min, and finally maintaing 99% solvent A for 6 min with a solvent flow 
rate of 0.650 mL/min. The injection was performed directly into the ESI source, the temperature of 
which was maintained at 500 oC, and the mass detector was measured under the optimized parameters. 
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Mass spectra were acquired in negative ESI mode and executed using the Masslynx4.1 software 
(Waters). The spectral analysis conditions are given in Table S1 and Table S2 [17]. Analytical 
Parameters of UPLC-MS/MS Method Validation are given in Table S3 and the purity of the standards, 
calibration curve and correlation coefficient for phenolic compounds are listed in Table S4. 
 
2.6. Statistical Analysis 
 
The analysis of phenolic compound contents in each propolis sample was conducted in triplicate 
and the results were expressed as mean ± standard deviation (SD). The data were analyzed by two way 
analysis of variance (ANOVA), followed by Tukey’s HSD Test with a = 0.05, using SPSS v. 16.0 
program. 
 
3.  Results and Discussion  
 
3.1. Biofilm Inhibition Activity of Propolis Extracts 
 
Development of alternative therapies for curing biofilm infections is one of the attractive areas 
for researchers as the biofilm is more resistant to antibiotics compared to planktonic cells. S. aureus 
strains, especially methicillin sensitive S. aureus (MSSA) and methicillin resistant S. aureus (MRSA), 
cause a wide range of life-threatening infections by forming biofilms. Propolis is known for its 
antimicrobial properties and there are many related reports in the literature [9,18,19]. However, there 
is no adequate information related to the antibiofilm properties of propolis against MSSA or MRSA 
bacteria. This study is focused on antibiofilm effect of propolis against MSSA strains as well as its 
chemical composition. 
In order to determine the biofilm inhibition activiy of two propolis samples (collected in 2013 
and 2012) in different concentrations (0.1, 0.2, 0.3, 0.4 and 0.5 mg/mL) against clinical pathogen 
bacteria, a standard quantitative biofilm assay method was used (Figure 1-2). Although a good 
antibiofilm activity was obtained almost for all the concentrations against the tested bacteria, the 
results appeared to be dose-related. While the biofilm inhibition percentages of BP-1 ranged from 
23.68% to 82.00% for MSSA M10 (Figure 1A), from 37.26% to 96.45% for MSSA M18 (Figure 1B), 
from 35.79% to 92.89% for MSSA M20 (Figure 1C) and from 24.59% to 85.00% for S. aureus ATCC 
33862 (Figure 1D), the biofilm inhibition rates of BP-2 ranged from 20.12% to 80.00% for MSSA 
M10 (Figure 2A), from 33.02% to 92.63% for MSSA M18 (Figure 2B), from 25.65% to 87.14% for 
MSSA M20 (Figure 2C) and from 20.35% to 78.00% for S. aureus ATCC 33862 (Figure 2D). These 
results indicated that the maximum inhibition of biofilm formation was obtained using the ethyl 
acetate extract. While the ethyl acetate extracts of BP-1 inhibited the biofilm formation of MSSA M18 
with 96.45% rate at 0.5 mg/mL concentration, the hexan  and ethanol extracts displayed 62.04% and 
92.00% biofilm inhibition activities against MSSA M18, respectively, for the same concentration 
(Figure 1B). In addition, the biofilm biomass of MSSA M18 was inhibited at 57.80%, 85.98% and 
92.63% by the hexane, ethyl acetate and ethanol extracts of BP-2, respectively, at 0.5 mg/mL 
concentration (Figure 2B). On the other hand, the ethanol extracts of propolis samples exhibited 
effective biofilm inhibition activity against the tsted bacteria, as well. In a seperate study, S. aureus 
biofilm development on inert substratum was inhibited by propolis ethanol extracts at a concentration 
of 0.1875 mg/mL [20]. Similarly, ethanol extract ofpropolis, obtained from Brazil, showed 3.1 
mg/mL MIC value against planktonic Staphylococcus aureus ATCC 25923 cells [21]. There are 
various studies available in the literature about an ibiofilm activity of propolis against such 
microorganisms. For example, the ethanolic extracts of propolis (EEPs) were fractionated into hexane 
(H-fr), chloroform, ethyl acetate and ethanol. The ability of the four fractions and EEP to inhibit 
Streptococcus mutans and Streptococcus sobrinus growth and adherence to a glass surface was 
examined by Hayacibara et al. [22]. In another study, Bulman et al. [23] reported that propolis 
disrupted the QS bacterial signaling system of five Escherichia coli in liquid- and agar-based 
bioassays and in C18 reverse-phase thin-layer plateassays. Swarming motility of the opportunistic 
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pathogen, Pseudomonas aeruginosa PAO1 and its AHL-dependent LasR- and RhlR-based QS 
behaviors were also inhibited by propolis. On the other hand, Duarte et al. [24] showed that fatty acids 
(oleic, palmitic, linoleic and stearic) were the main compounds identified in EEP and EEH, and these 
extracts did not show major effects on the viability of mutans streptococci biofilms. Furthermore, the 
inhibition of Candida albicans biofilm formation by propolis extracts was also reported [25].   
 
3.2. Effect of Propolis Extracts on Established Biofilms 
 
It was observed that the established biofilm was gradually damaged upon treatment with 
different concentrations of propolis (0.5-20 mg/L) in 24 h. Generally, the biofilm reduction rates 
increased with the increase in extract concentrations (Table 1). The maximum biofilm reduction of 
BP-1 was obtained at 60.45% against S. aureus ATCC 33862 with the ethyl acetate extract, and 57.97 
and 57.39% against MSSA M10 with the ethyl acetate and ethanol extracts, respectively. BP-2 also 
showed the maximum biofilm reduction rate, 55.40%, on S. aureus ATCC 33862 with the ethyl 
acetate extract.  
 
 
Figure 1. The effect of hexane, ethyl acetate and ethanol extracts of BP-1 on the biofilm formation of MSSA 
M10 (A), M18 (B), M20 (C) and S. aureus ATCC 33862 (D) bacteria, expressed as percentage inhibition 
evaluated by the Crystal Violet staining. 
 
Consequently, the extracts exhibited good antibiofilm activity either by inhibition of biofilm 
formation (Figure 1, 2) or reduction of the preformed biofilms (Table 1) in different rates against the
tested bacteria. According to the Figures (1-2) and Table 1, BP-1, collected in 2013, was slightly more 
active than BP-2, collected in 2012. The contents of flavonoids, flavones and flavonols show 
differences according to the year propolis collected [26]. Also, the ethanol and the ethyl acetate 
extracts of the propolis samples were more effectiv on S. aureus biofilms compared to the hexane 
extracts (Figure 1, 2 and Table 1).  
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Figure 2. Inhibition effect of hexane, ethyl acetate and ethanol extracts of BP-2 on biofilm formation of MSSA 
M10 (A), M18 (B), M20 (C) and S. aureus ATCC 33862 (D) bacteria, expressed as percentage inhibition, 
evaluated by the Crystal Violet staining. 
 
 
 
Figure 3. Plot of loadings of the first and second principal components, possessing different varibles: year of 
propolis collected: BP1, BP2; extraction solvents: EX1 (hexane), EX2 (ethanol) and EX3( ethyl acetate)
Scores on PC 2 (90.0%) 
BP2/EX1 
BP1/EX1 
BP1/EX2 
BP2/EX2 
BP1/EX3 
BP2/EX3 
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Table 1. Biofilm reduction percentage of propolis extracts  (%) ± SD. 
Bacteria Extracts 
Concentrations of BP-1 (mg/mL) Concentrations of BP-2 (mg/mL) 
0.5 1 5 10 15 20 0.5 1 5 10 15 20 
MSSA 
M10 
HEX 15.56±0.9 18.79±6.3 24.70±3.0 30.18±3.2 38.57±1.8 38.04±5.0 15.65±5.3 18.97±6.6 23.70±5.5 26.18±4.6 30.57±6.8 32.04±7.0 
ETA 27.59±8.3 31.40±7.0 39.51±4.6 51.24±2.8 57.22±0.5 57.97±8.6 22.16±0.0 30.66±1.3 32.92±7.6 45.67±4.2 49.1 ±2.8 53.42±3.1 
ETOH 25.67±5.6 33.75±5.9 34.93±5.9 42.05±1.2 50.07±1.9 57.39±1.1 19.60±0.9 27.87±4.1 33.00±3.2 42.56±7.5 46.57±2.2 50.45±2.5 
MSSA 
M18 
HEX 20.58±4.0 21.48±0.2 22.02±0.3 27.34±8.8 29.23±5.0 30.50±3.1 11.36±3.6 10.95±1.9 13.17±2.8 14.70±3.5 25.70±2.5 25.88±1.8 
ETA 31.70±3.7 34.04±8.6 40.80±9.4 44.36±5.3 47.66±4.8 50.9 ±3.7 28.02±6.7 31.40±6.6 40.07±0.9 44.68±1.6 47.8 ±7.5 47.57±4.4 
ETOH 27.21±1.8 29.49±1.8 32.73±3.0 34.16±6.7 37.05±0.6 39.45±1.1 27.74±1.2 28.85±9.7 28.62±0.6 29.61±2.4 31.70±8.0 33.45±8.9 
MSSA 
M20 
HEX 16.41±1.3 20.71±1.5 21.64±3.8 22.20±4.8 22.86±2.3 26.89±1.4 20.28±7.3 24.34±7.3 25.43±1.1 25.30±1.4 25.87±1.4 28.05±1.8 
ETA 31.22±2.9 37.33±1.6 38.76±4.6 39.76±1.5 44.92±1.1 44.01±1.7 31.29±5.4 34.01±6.2 40.60±4.6 40.68±6.1 45.87±9.4 46.85±1.1 
ETOH 24.64±2.6 34.31±3.4 37.68±9.8 37.92±0.6 38.76±8.9 38.54±3.2 21.79±3.6 24.87±1.7 29.86±5.5 34.18±3.5 36.92±2.3 36.38±9.6 
S. aureus 
ATCC 
33862 
HEX 14.50±5.0 16.30±1.2 18.58±1.6 21.88±9.6 27.21±1.3 29.61±2.9 16.77±1.7 21.92±1.1 22.01±2.0 23.06±1.2 27.26±1.1 27.34±2.2 
ETA 38.41±7.1 49.25±1.0 48.55±3.5 52.00±6.8 59.49±3.4 60.45±6.5 28.58±7.3 34.05±3.2 45.43±4.4 50.94±5.2 53.81±2.0 55.40±2.2 
ETOH 29.34±0.5 38.82±3.2 41.30±1.2 41.87±4.0 42.25±1.2 46.51±1.6 18.47±1.1 26.44±1.2 35.04±9.2 41.46±8.4 45.47±0.1 45.34±1.7 
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3.3. Phenolic Compound Content of Propolis 
 
Phenolic compounds of the BP-1 and BP-2 samples were identified and quantified by using 
UPLC-ESI-MS/MS technique, based on retention time and ccording to their mass-to-charge ratio 
(Table 2) [27]. 
Twenty-four phenolic compounds (homogentisic, 3,4-dihy roxybenzoic (protocatechuic), 
gentisic, p-hydroxy benzoic, vanillic, caffeic, syringic, p-coumaric, trans-cinnamic, ferrulic and trans-
2-hydroxy cinnamic acids, rutin, myricetin, 3,4-dihydroxybenzaldehyde, quercetin, naringenin, 
genistein, apigenin, kaempferol, chrysin and vanillin) were determined in all three fractions of the 
propolis samples (Table 2), and the results are givn n Figure S1. On the other hand, pyrogallol, 
galantamine, catechin hydrate, epicatechin, catechin gallate and resveratrol were not detected, and 
while luteolin was not found in BP-2, no hesperetin was identified in BP-1. Also, ferulic, caffeic and 
gentisic acids were the most abundant phenolic compounds found in the extracts. While the ethanol 
extracts of propolis samples presented high quantity, the hexane extracts were lower in amount. The 
number of the identified phenolic compounds, obtained from Bartın propolis in the present study were 
found to be higher compared to that of reported by Erdogan  et al. [28], who studied propolis from 
different regions of Turkey, and detected thirteen compounds, using a different methodology.  
ANOVA of the data showed that the year of collection (BP-1, BP-2) and the extraction 
solvents (hexane, ethanol and ethyl acetate) have st tistically significant effect (p : 0.05) on phenolic 
compound contents of propolis. The effect of interaction between two main factors was also found to 
be significant (p : 0.05) (Table 2).  
Principal component analysis (PCA), i.e. a statistical process, was applied to the extracted 
phenolic compounds from the propolis samples, using all three extraction solvents concurrently in 
order to discover groupings and indicate that these r ults displayed significant differences, based on 
propolis and the extraction solvent (Table S5). PSA of the data generated two significant principal 
components (PCs), explaining 65.5%, 90.0% of the variance. Figure 3 (PC1 vs PC2) is a plot of 
principal component loadings of propolis, extraction solvents and phenolic compounds on the first and 
the second principal components. The maximum biofilm reduction of BP-1 and BP-2 against S. aureus 
ATCC 33862 was produced by the ethyl acetate extract (Figure 3). This level of biofilm reduction was 
followed by the ethanol and hexane extracts, respectively, as delineated in Figure 3. 
A LSD multiple-range test was used to perform comparisons among different extraction 
solvents (Table S6). A statistically significant difference was obtained among 3,4-dihydroxybenzoic 
acid, gentisic acid, p-hydroxy benzoic acid, vanillic acid, caffeic acid, syringic acid, p-coumaric acid, 
ferulic acid, trans-cinnamic acid, naringenin, genistein, kaempferol and chrysin in terms of extraction 
solvent, and the higher statistical significance was observed in ethyl acetate for both propolis types 
(BP-1, BP-2). However, no statistically significant difference was found between hexane and ethanol 
extraction solvents for pyrocatechol, vanillin, rutin, trans-2-hydroxy cinnamic acid, myricetin and 
quercetin. 
The antibiofilm activity results were confirmed by UPLC-ESI-MS/MS and the principal 
component analyses.  Although twenty-four compounds were detected in the propolis samples, general 
phenolic contents of BP-1 was found to be higher than BP-2 (Table 2). While the ferulic acid of 
ethanol extract of BP-1 was 112500 µg/g, it was 98661 µg/g for BP-2 (Table 2). Similarly, Veloz et al.
[26] investigated the polyphenol and flavonoid contents and antibiofilm activity of Chilean propolis 
samples, collected in three different years (2008, 2010 and 2011). They reported that the second 
extract (CEP2), which contained higher polyphenol and flavonoid contents showed the most effective 
biofilm inhibition activity. Specifically, the propolis samples, used in that study, contained higher 
amount of caffeic acid, which is reported to be an anti-quorum sensing component in propolis sample 
[29]. Thus, it is responsible for antibiofilm activi y of propolis. 
As a conclusion, as it was revealed from the analyses of the phenolic compounds of the propolis 
samples, the ethyl acetate and ethanol extracts had t e higher amount of phenolic contents. 
Accordingly, it has been determined that the biofilm reduction rates of the ethyl acetate and ethanol 
extracts of propolis were better than that of the hexane extract of propolis. The ethyl acetate and 
ethanol extracts displayed high antibiofilm activity, yet hexane extracts were fairly active. This also 
indicated notable consistency between the phenolic c ntent and the biofilm inhibition rate/antibiofilm 
activity.   
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                         Table 2. Phenolic contents (µg/g propolis extract) of propolis samples. 
 BP1 BP2 
Compounds Hexane Ethanol Ethyl acetate Hexane Ethanol Ethyl acetate 
Pyrogallol < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Homogentisic acid 903.0d 3255.0b 5748.3a 61.29f 353.41e 1268.0c 
3,4-Dihydroxybenzoic acid 253.22e 652.32c 984.71b 51.96f 453.65d 1339.8a 
Gentisic acid 199.56f 2122.5d 5232.0b 537.24e 3133.4c 6897.8a 
Pyrocatechol 10.73f 23.49e 160.97c 56.84d 235.66b 986.72a 
Galantamine < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
p-hydroxy benzoic acid 63.45f 254.60d 1229.80c 137.61e 1755.20b 3360.60a 
3,4-dihydroxybenzaldehyde 101.86b 325.76b 689.46b 257.73b 2531.2a 2342.9a 
Catechin hydrate < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Vanillic acid 204.6e 1846.1c 3263.7b 1159.3d 3255.3b 6534.2a 
Caffeic acid 3522.8e 16881.0c 23521.0a 2322.5f 10416.0d 19100.0b 
Syringic acid 523.64e 1546.9b 1984.2a 246.53f 956.04d 1337.3c 
Vanillin 9.31f 24.97e 127.45c 102.98d 225.16b 549.40a 
p-coumaric acid 1207.5f 3356.0d 5977.0b 2082.2e 4326.1c 7568.4a 
Ferulic acid 12878e 112500c 156600a 9627.7f 98661d 136800b 
Epicatechin < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Catechin gallate < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
Rutin 126.73f 583.09d 1046.6b 236.45e 646.58c 3565.1a 
trans-2-hydroxy cinnamic acid 540.35d 995.70b 1536.1a 99.78f 126.39e 887.14c 
Myricetin 55.87f 99.63e 364.44c 200.71d 532.69b 1206.70a 
Resveratrol < LOQ < LOQ < LOQ < LOQ < LOQ < LOQ 
trans-cinnamic acid 48.14d 124.17c 458.01b 130.01c 457.70b 846.90a 
Luteolin 15.93c 86.76b 246.54a 0.012d 0.001d 0.002d 
Quercetin 47.93f 121.05e 356.08c 155.43d 445.6b 1006.1a 
Naringenin 245.43e 1044.30c 1986.40a 114.60f 345.80d 1148.2b 
Genistein 364.76d 997.32b 1007.6b 126.23e 757.85c 2008.2a 
Apigenin 18.85d 49.06c 129.42b 54.45c 124.59b 501.41a 
Kaempferol 121.77e 421.0d 1126.2b 100.61f 647.92c 1355.7a 
Hesperetin 0.0003d 0.005d 0.0005d 12.25c 39.47b 125.42a 
Chrysin 9.811e 28.306c 89.065a 9.464e 19.122d 60.576b 
                            Means followed by the same letter in the same column are not significantly different from each other (p : 0.05) 
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